https://clinicaltrials.gov/ct2/show/NCT04091360?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease Condition : COPD Interventions : Drug: Ensifentrine 100mcg; Drug: Ensifentrine 300mcg; Drug: Ensifentrine 1000mcg; Drug: Ensifentrine 3000mcg; Drug: Ensifentrine 6000mcg; Drug: Placebos Sponsors : Verona Pharma plc; Iqvia Pty Ltd Recruiting NCT04091360 Mon, 16 Sep 2019 12:00:00 EDT
ensifentrine
Verona Pharma announces publication of Phase 2b clinical trial results for ensifentrine, a maintenance treatment for chronic obstructive pulmonary disease (COPD)
https://www.biospace.com/article/releases/verona-pharma-announces-publication-of-key-phase-2b-copd-data-in-respiratory-researchpaper-demonstrates-ensifentrine-s-potential-in-improving-lung-function-and-quality-of-life-symptoms Verona Pharma Announces Publication of Key Phase 2b COPD Data – Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms
Verona Pharma Reports Positive Top-line Data in Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy
https://www.globenewswire.com/news-release/2020/01/13/1969219/0/en/Verona-Pharma-Reports-Positive-Top-line-Data-in-4-Week-Phase-2b-COPD-Study-with-Nebulized-Ensifentrine-on-Top-of-Tiotropium-Therapy.html Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial for Ensifentrine in moderate-to-severe COPD
https://www.biospace.com/article/releases/verona-pharma-completes-enrollment-in-phase-2b-clinical-trial-with-nebulized-ensifentrine-in-moderate-to-severe-copdresults-to-inform-development-plan-and-dose-selection-for-phase-3/ Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPDResults to Inform Development Plan and Dose Selection for Phase 3
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine (RPL554) in COPD at CHEST 2019
http://www.globenewswire.com/news-release/2019/10/15/1929421/0/en/Verona-Pharma-to-Present-Phase-2-Symptom-Data-with-Ensifentrine-in-COPD-at-CHEST-2019.html Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD
https://www.ncbi.nlm.nih.gov/pubmed/31474120?dopt=Abstract https://www.ncbi.nlm.nih.gov/pubmed/31474120?dopt=Abstract Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Related Articles Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin Investig Drugs. 2019 Sep 01;:1-7 Authors: Cazzola M, Calzetta L, Rogliani P, Matera MG Abstract Introduction: A compound that simultaneously inhibits PDE3 and PDE4 should increase airway […]
